1. Home
  2. IPO
  3. Akums Drugs Pharmaceuticals Ltd Ipo
34484
Off
akums drugs ipo

Akums Drugs & Pharmaceuticals IPO

  • Status: Closed
  • RHP:
  • ₹ 14,212 / 22 shares

    Minimum Investment

IPO Listing Details

  • Listing Date

    06 Aug 2024

  • Listing Price

    ₹725.00

  • Listing Change

    6.77%

  • Last Traded Price

    ₹609.65

IPO Details

  • Open Date

    30 Jul 2024

  • Close Date

    01 Aug 2024

  • IPO Price Range

    ₹ 646 to ₹ 679

  • IPO Size

    ₹ 1856.74 Cr

  • Listing Exchange

    BSE, NSE

  • Listing Date

    06 Aug 2024

With just a few clicks, Invest in IPO's!

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Subscription Status Objective Financials SWOT FAQ Contacts

IPO Timeline

Akums Drugs & Pharmaceuticals IPO Subscription Status

Last Updated: 01 August 2024 6:01 PM by 5Paisa

Last Updated: 1st August 2024, 5:15 PM by 5paisa

Akums Drugs and Pharmaceuticals IPO is set to open on 30 July 2024 and will close on 1 August 2024. The company is a significant pharmaceutical contract development and manufacturing organization.

The IPO includes a fresh issue of 1,00,14,727 shares aggregating up to ₹680.00 Cr and it also includes an offer for sale of 1,73,30,435 shares aggregating up to ₹1,176.74 Cr. The price range is ₹646 to ₹679 per share and the lot size is 22 shares. 

The allotment is scheduled to be finalized on 2 August 2024. It will go public on BSE & NSE, with a tentative listing date of 6 August 2024.

ICICI Securities Limited, Axis Bank Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited are the book-running lead managers, while Link Intime India Private Ltd is the registrar. 

Objectives Of Akums Drugs IPO

1. Repayment/ prepayment of indebtedness of the company and its Subsidiaries.
2. Funding incremental working capital requirements.
3. Pursuing inorganic growth initiatives through acquisitions.
4. General corporate purposes.

Akums Drugs IPO Video

 

 

Akums Drugs IPO Size

Types Size (₹Cr)
Total IPO size 1856.74
Offer for sale 680.00
Fresh issue 1176.74

Akums Drugs IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 22 ₹14,938
Retail (Max) 13 286 ₹1,94,194
S-HNI (Min) 14 308 ₹2,09,132
S-HNI (Max) 66 1452 ₹9,85,908
B-HNI (Min) 67 1474 ₹10,00,846

Akums Drugs IPO Reservation

Investors Category Subscription (times) Shares Offered Shares bid for Total Amount (Cr.)
QIB 90.09 81,37,276 73,31,17,770 49,778.70
NII (HNI) 42.10 40,68,637 17,12,78,294 11,629.80
Retail 20.73 27,12,424 5,62,31,318 3,818.11
Total 63.42 1,51,62,239 96,16,32,144 65,294.82

Akums Drugs IPO Anchor Allocation

Anchor Bid Date 29 July, 2024
Total no. of shares offered 12,205,912
Portion Size for Anchor Investors  828.78 Cr.
Lock in Period for 50% shares (30 days) 1 September, 2024
Lock in Period for rest of shares (90 days) 31 October, 2024

Akums Drugs and Pharmaceuticals Limited, founded in 2004, is a significant pharmaceutical contract development and manufacturing organization (CDMO) that offers a diverse range of pharmaceutical goods and services in India and throughout the world. 

The firm provides comprehensive solutions that include product development, manufacturing, formulation research and development (R&D), regulatory dossier preparation and submission, and a variety of testing services. Additionally, Akums manufactures and sells branded pharmaceuticals and active pharmaceutical ingredients (APIs).

As a CDMO, Akums manufactures a wide variety of dosage forms, including tablets, capsules, liquid medications, vials, ampoules, blow-filled closures, topical treatments, eye drops, dry powder injections, and gummy bears, among others. The firm has a portfolio of 4,025 marketed formulations spanning more than 60 dosage formats. In fiscal year 2023, Akums produced formulations for 26 of India's top 30 pharmaceutical businesses by sales.

The firm runs ten manufacturing units for its CDMO business, with a total annual production capacity of 49.21 billion units as of September 30, 2023. Plans are ongoing to increase this capacity with the installation of two more manufacturing units, which will be operational in fiscal year 2025. 

Several Akums facilities have been accredited by worldwide regulatory authorities, including the European Good Manufacturing Practice (EU-GMP), World Health Organization Good Manufacturing Practice (WHO-GMP), and the United States National Sanitation Foundation (US NSF).

As of September 30, 2023, Akums Drugs & Pharmaceuticals employed 16,463 people, including 7,211 full-time employees and 9,252 contract workers.

Peers

● Divi’s Laboratories
● Suven Pharma
● Gland Pharma
● Torrent Pharma
● Alkem Laboratories
● Eris Lifesciences
● JB Chemicals
● Mankind Pharma
● Innova Captab

For More Information

Webstory on Akums Drugs IPO

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY24 FY23 FY22
Revenue from operations 4,212.21 3,700.93 3,694.52
EBITDA 157.01 384.06 -69.09
PAT 0.79 97.82 -250.87
Particulars (in Rs. Crores) FY24 FY23 FY22
Total Assets 3,516.37 3,266.53 3,069.05
Share Capital 0.29 0.29 0.14
Total Borrowings 491.56 536.97 357.95
Particulars (in Rs. Crores) FY24 FY23 FY22
Net Cash Generated From / (used in) operating activities 498.26 176.63 31.85
Net Cash Generated From / (used in) investing activities -330.41 -304.70 -234.82
Net Cash Generated From / (used in) financing activities -108.02 124.54 236.04
Net Increase (Decrease) In Cash And Cash Equivalents 59.82 -3.53 33.07


Strengths

1. Akums provides end-to-end solutions and this comprehensive service offering attracts a wide range of clients and enhances customer loyalty.
2. The company manufactures a diverse range of dosage forms.
3. In FY 2023, Akums manufactured formulations for 26 of the top 30 pharmaceutical companies in India by revenue. 
4. Akums operates 10 manufacturing units with a combined annual production capacity of 49.21 billion units. 
5. The company's facilities have received accreditations from major global regulatory bodies.
6. Akums plans to expand its production capacity with two additional units to be commissioned in FY 2025. 
 

Risks

1. The pharmaceutical industry is heavily regulated. 
2. The CDMO sector is highly competitive, with numerous players vying for market share. 
3. The company’s performance is closely tied to the pharmaceutical industry's health. 
4. Manufacturing pharmaceutical products involves complex processes and strict quality control. 
5. Disruptions in the supply chain can affect production schedules and costs.
6. While expansion plans can drive growth, they also involve significant capital expenditure and operational risks. 

Will You Apply for Akums Drugs & Pharmaceuticals IPO?

Yes No Maybe

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
footer_form

FAQs

Akums Drugs and Pharmaceuticals IPO opens from 30th July to 1st August 2024.

The size of Akums Drugs and Pharmaceuticals IPO is ₹1,856.74 Cr.

The price of Akums Drugs and Pharmaceuticals IPO is fixed at ₹646 to ₹679 per share. 

To apply for Akums Drugs and Pharmaceuticals IPO, follow the steps given below:

●    Login to your 5paisa account and select the issue in the current IPO section    
●    Enter the number of lots and the price at which you wish to apply for the Akums Drugs and Pharmaceuticals IPO.    
●    Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    

You will receive a mandate notification to block funds in your UPI app.

The minimum lot size of Akums Drugs and Pharmaceuticals IPO is 22 shares and the investment required is ₹14,938.

The share allotment date of Akums Drugs and Pharmaceuticals IPO is 2nd August 2024

The Akums Drugs and Pharmaceuticals IPO will be listed on 6th August 2024.

ICICI Securities Limited, Axis Bank Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited are the book-running lead managers for Akums Drugs and Pharmaceuticals IPO.
 

Akums Drugs and Pharmaceuticals plans to utilize the raised capital from the IPO for:

● Repayment/ prepayment of indebtedness of the company and its Subsidiaries.
● Funding incremental working capital requirements.
● Pursuing inorganic growth initiatives through acquisitions.
● General corporate purposes.